Literature DB >> 15249800

Angiotensin-converting enzyme inhibitors side effects--physiologic and non-physiologic considerations.

Domenic A Sica1.   

Abstract

Angiotensin-converting enzyme (ACE) inhibitors are increasingly recognized as having an important role in the treatment of hypertension and/or end-organ disease. The sheer number of ACE inhibitors in the United States--now numbering 10 different chemical entities--has created a sense of comfort with these compounds, which is particularly evident when these compounds are used in the patient with essential hypertension; conversely, when comorbid conditions are present in the ACE inhibitor-treated patient, circumstances change and physician vigilance becomes more of a necessity. ACE inhibitor therapy in patients with either cardiac and/or renal disease is as much an art as it is a science, and even in the most skilled hands can prove a challenging undertaking. This review discusses the physiologic and non-physiologic basis for side effects with ACE inhibition.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15249800      PMCID: PMC8109542          DOI: 10.1111/j.1524-6175.2004.02866.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  51 in total

1.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.

Authors:  Salim Yusuf; Bertram Pitt; Clarence E Davis; William B Hood; Jay N Cohn
Journal:  N Engl J Med       Date:  1991-08-01       Impact factor: 91.245

2.  Hyperkalemia in azotemic patients during angiotensin-converting enzyme inhibition and aldosterone reduction with captopril.

Authors:  S C Textor; E L Bravo; F M Fouad; R C Tarazi
Journal:  Am J Med       Date:  1982-11       Impact factor: 4.965

Review 3.  Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology.

Authors:  Z H Israili; W D Hall
Journal:  Ann Intern Med       Date:  1992-08-01       Impact factor: 25.391

4.  ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K Study Group.

Authors:  G L Bakris; M Siomos; D Richardson; I Janssen; W K Bolton; L Hebert; R Agarwal; D Catanzaro
Journal:  Kidney Int       Date:  2000-11       Impact factor: 10.612

Review 5.  Treatment of ACE inhibitor-induced cough.

Authors:  C A Luque; M Vazquez Ortiz
Journal:  Pharmacotherapy       Date:  1999-07       Impact factor: 4.705

6.  Hyperkalaemia in congestive heart failure patients using ACE inhibitors and spironolactone.

Authors:  Constança S Cruz; Alvaro A Cruz; Carlos A Marcílio de Souza
Journal:  Nephrol Dial Transplant       Date:  2003-09       Impact factor: 5.992

Review 7.  Hyperkalemia, congestive heart failure, and aldosterone receptor antagonism.

Authors:  Domenic A Sica; Todd W B Gehr; Clyde Yancy
Journal:  Congest Heart Fail       Date:  2003 Jul-Aug

Review 8.  Ramipril: a review of its use in the prevention of cardiovascular outcomes.

Authors:  Gregory T Warner; Caroline M Perry
Journal:  Drugs       Date:  2002       Impact factor: 9.546

9.  Association between ACE inhibitors use and headache caused by nitrates among hypertensive patients: results from the Italian group of pharmacoepidemiology in the elderly (GIFA).

Authors:  G Onder; M Pahor; G Gambassi; A Federici; A Savo; P Carbonin; R Bernabei
Journal:  Cephalalgia       Date:  2003-11       Impact factor: 6.292

10.  Intermittent visceral edema induced by long-term enalapril administration.

Authors:  Katherine K Orr; James R Myers
Journal:  Ann Pharmacother       Date:  2004-03-23       Impact factor: 3.154

View more
  17 in total

Review 1.  The evolution of renin-angiotensin blockade: angiotensin-converting enzyme inhibitors as the starting point.

Authors:  Domenic A Sica
Journal:  Curr Hypertens Rep       Date:  2010-04       Impact factor: 5.369

Review 2.  Targeting Metalloenzymes for Therapeutic Intervention.

Authors:  Allie Y Chen; Rebecca N Adamek; Benjamin L Dick; Cy V Credille; Christine N Morrison; Seth M Cohen
Journal:  Chem Rev       Date:  2018-09-07       Impact factor: 60.622

3.  Association of angiotensin-converting enzyme inhibitor therapy initiation with a reduction in hemoglobin levels in patients without renal failure.

Authors:  Eran Leshem-Rubinow; Arie Steinvil; David Zeltser; Shlomo Berliner; Ori Rogowski; Raanan Raz; Gabriel Chodick; Varda Shalev
Journal:  Mayo Clin Proc       Date:  2012-11-07       Impact factor: 7.616

4.  Incidence of risk factors for developing hyperkalemia when using ACE inhibitors in cardiovascular diseases.

Authors:  Omalhassan Amir; Yahaya Hassan; Azmi Sarriff; Ahmed Awaisu; Noorizan Abd Aziz; Omar Ismail
Journal:  Pharm World Sci       Date:  2009-03-03

5.  LCZ696, a First-in-Class Angiotensin Receptor-Neprilysin Inhibitor: The First Clinical Experience in Patients With Severe Hypertension.

Authors:  Kazuomi Kario; Yuko Tamaki; Naoko Okino; Hiromi Gotou; Min Zhu; Jack Zhang
Journal:  J Clin Hypertens (Greenwich)       Date:  2015-09-24       Impact factor: 3.738

6.  Angiotensin-converting enzyme inhibitor use in the year 2005.

Authors:  Domenic A Sica
Journal:  J Clin Hypertens (Greenwich)       Date:  2005-08       Impact factor: 3.738

7.  Isolation, purification and molecular mechanism of a peanut protein-derived ACE-inhibitory peptide.

Authors:  Aimin Shi; Hongzhi Liu; Li Liu; Hui Hu; Qiang Wang; Benu Adhikari
Journal:  PLoS One       Date:  2014-10-27       Impact factor: 3.240

8.  Dose-Related Antihypertensive Properties and the Corresponding Mechanisms of a Chicken Foot Hydrolysate in Hypertensive Rats.

Authors:  Anna Mas-Capdevila; Zara Pons; Amaya Aleixandre; Francisca I Bravo; Begoña Muguerza
Journal:  Nutrients       Date:  2018-09-12       Impact factor: 5.717

9.  Cardiovascular events in hypertension trials of Angiotensin-converting enzyme inhibitors.

Authors:  William J Elliott
Journal:  J Clin Hypertens (Greenwich)       Date:  2005-08       Impact factor: 3.738

Review 10.  Management protocols for chronic heart failure in India.

Authors:  S Mishra; J C Mohan; Tiny Nair; V K Chopra; S Harikrishnan; S Guha; S Ramakrishnan; S Ray; R Sethi; U C Samal; K Sarat Chandra; M S Hiremath; A K Banerjee; S Kumar; M K Das; P K Deb; V K Bahl
Journal:  Indian Heart J       Date:  2017-11-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.